Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 8/20 | 0.55 |
| ▸ | RAB9A | P51151 | 8/20 | 0.55 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | TP53 | P04637 | 2/20 | 0.47 |
| ▸ | TRPV1 | Q8NER1 | 6/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | NR1H4 | Q96RI1 | 3/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2297644 | 0.93 | NPC1 (0.48) | NPC1RAB9AKCNK9TRPV1NR1H4 | |
| SCHEMBL2295674 | 0.91 | NPC1 (0.56) | NPC1RAB9ASMN1; SMN2TP53LMNA | |
| SCHEMBL2295869 | 0.91 | NPC1 (0.50) | NPC1RAB9ASMN1; SMN2TP53TRPV1 | |
| SCHEMBL2296039 | 0.90 | NPC1 (0.52) | NPC1RAB9ASMN1; SMN2TP53LMNA | |
| SCHEMBL2294968 | 0.90 | NPC1 (0.59) | NPC1RAB9ASMN1; SMN2TP53LMNA | |
| SCHEMBL2296016 | 0.89 | NPC1 (0.50) | NPC1RAB9ASMN1; SMN2TP53LMNA | |
| SCHEMBL2294143 | 0.89 | NPC1 (0.53) | NPC1RAB9ASMN1; SMN2TP53LMNA | |
| SCHEMBL2292563 | 0.89 | RAB9A (0.50) | NPC1RAB9ASMN1; SMN2TP53LMNA | |
| SCHEMBL2296419 | 0.89 | NPC1 (0.49) | NPC1RAB9ASMN1; SMN2TP53TRPV1 | |
| SCHEMBL2299737 | 0.89 | NPC1 (0.49) | NPC1RAB9ASMN1; SMN2TP53LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8003806-B2 | Integrin antagonists useful as anticancer agents | OSI Pharmaceuticals, LLC (US) | 2011-08-23 | — | — | US | claimed |
| US-20060116383-A1 | Integrin antagonists useful as anticancer agents | ALCATEL LUCENT (FR) | 2006-06-01 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060116383-A1 | Integrin antagonists useful as anticancer agents | ITGB5, ITGA5, ITGB1 | NPC1 2770/4885RAB9A 1893/4885KCNK9 2334/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.